Tìm theo
Clotrimazole
Các tên gọi khác (9 ) :
  • 1-((2-Chlorophenyl)diphenylmethyl)-1H-imidazole
  • 1-(alpha-(2-Chlorophenyl)benzhydryl)imidazole
  • 1-(O-Chloro-alpha,alpha-diphenylbenzyl)imidazole
  • 1-(o-Chloro-α,α-diphenylbenzyl)imidazole
  • 1-(o-Chlorotrityl)imidazole
  • 1-(α-(2-Chlorophenyl)benzhydryl)imidazole
  • Clotrimazole
  • Lotrimin (tn)
  • Mycelex (tn)
Thuốc điều trị bệnh da liễu
Thuốc Gốc
Small Molecule
CAS: 23593-75-1
ATC: A01AB18, D01AC01, G01AF02
ĐG : Actavis Group , http://www.actavis.com
CTHH: C22H17ClN2
PTK: 344.837
An imidazole derivative with a broad spectrum of antimycotic activity. It inhibits biosynthesis of the sterol ergostol, an important component of fungal cell membranes. Its action leads to increased membrane permeability and apparent disruption of enzyme systems bound to the membrane. [PubChem]
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C22H17ClN2
Phân tử khối
344.837
Monoisotopic mass
344.108026261
InChI
InChI=1S/C22H17ClN2/c23-21-14-8-7-13-20(21)22(25-16-15-24-17-25,18-9-3-1-4-10-18)19-11-5-2-6-12-19/h1-17H
InChI Key
InChIKey=VNFPBHJOKIVQEB-UHFFFAOYSA-N
IUPAC Name
1-[(2-chlorophenyl)diphenylmethyl]-1H-imidazole
Traditional IUPAC Name
clotrimazole
SMILES
ClC1=CC=CC=C1C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
Độ tan chảy
154-156
Độ hòa tan
29.84 mg/mL
logP
6.1
logS
-5.4
pKa (Strongest Basic)
6.62
PSA
17.82 Å2
Refractivity
103.76 m3·mol-1
Polarizability
36.25 Å3
Rotatable Bond Count
4
H Bond Acceptor Count
1
H Bond Donor Count
0
Physiological Charge
0
Number of Rings
4
Bioavailability
1
Dược Lực Học : Clotrimazole, an imidazole derivative with a broad spectrum of antimycotic activity, inhibits biosynthesis of the sterol ergostol, an important component of fungal cell membranes. Its action leads to increased membrane permeability and apparent disruption of enzyme systems bound to the membrane. Betamethasone and clotrimazole are used together to treat cutaneous tinea infections. In studies in fungal cultures, the minimum fungicidal concentration of clotrimazole caused leakage of intracellular phosphorous compounds into the ambient medium with concomitant breakdown of cellular nucleic acids, and accelerated potassium etflux. Both of these events began rapidly and extensively after addition of the drug to the cultures. The primary action of clotrimazole is against dividing and growing organisms.
Cơ Chế Tác Dụng : An imidazole derivative with a broad spectrum of antimycotic activity. It inhibits biosynthesis of the sterol ergostol, an important component of fungal cell membranes. Its action leads to increased membrane permeability and apparent disruption of enzyme systems bound to the membrane. [PubChem] Clotrimazole interacts with yeast 14-α demethylase, a cytochrome P-450 enzyme that converts lanosterol to ergosterol, an essential component of the membrane. In this way, clotrimazole inhibits ergosterol synthesis, resulting in increased cellular permeability. Clotrimazole may also inhibit endogenous respiration, interact with membrane phospholipids, inhibit the transformation of yeasts to mycelial forms and the uptake of purine, impair triglyceride and/or phospholipid biosynthesis, and inhibit the movement of calcium and potassium ions across the cell membrane by blocking the ion transport pathway known as the Gardos channel.
Dược Động Học :
▧ Absorption :
Poorly and erratically absorbed orally, minimal vaginal or topical absorption.
▧ Protein binding :
90%
▧ Metabolism :
Hepatic (metabolized to inactive metabolites)
▧ Half Life :
2 hours
Độc Tính : Symptoms of overdose include erythema, stinging, blistering, peeling, edema, pruritus, urticaria, burning, and general irritation of the skin, and cramps.
Chỉ Định : For the local treatment of oropharyngeal candidiasis and vaginal yeast infections, also used in fungal infections of the skin such as ringworm, athlete's foot, and jock itch.
Tương Tác Thuốc :
  • Alvimopan Decreases levels by P-glycoprotein (MDR-1) efflux transporter. Can significantly increase systemic exposure to P-glycoprotein substrates.
  • Budesonide CYP3A4 Inhibitors (Moderate) such as clotrimazole may increase the serum concentration of Budesonide (Systemic, Oral Inhalation). Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor. This interaction is likely less severe with orally inhaled budesonide. Any patient receiving both budesonide and a moderate CYP3A4 inhibitor should be monitored closely for signs/symptoms of corticosteroid excess.
  • Colchicine CYP3A4 Inhibitors (Moderate) such as clotrimazole may increase the serum concentration of colchicine. Reduce colchicine dose (for gout flares: to 1.2 mg x 1 dose, with next dose no sooner than 3 days later; for Familial Mediterranean Fever: to no more than 1.2 mg/day) when using in combination with a moderate CYP3A4 inhibitor such as erythromycin or verapamil. Increase monitoring for colchicine-related toxicity when using such combinations. Use extra caution in patients with impaired renal and/or hepatic function.
  • Everolimus CYP3A4 Inhibitors (Moderate)such as clotrimazole may increase the serum concentration of everolimus. The prescribing information for the Afinitor branded everolimus product lists indication-specific recommendations for managing this interaction.
  • Fentanyl CYP3A4 Inhibitors (Moderate) such as clotrimazole may increase the serum concentration of fentanyl. Concurrent use of fentanyl with any CYP3A4 inhibitor may result in increased fentanyl concentrations and could increase or prolong adverse effects, including potentially fatal respiratory depression. Patients receiving fentanyl and any CYP3A4 inhibitor should be closely monitored for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.
  • Halofantrine CYP3A4 Inhibitors (Moderate) such as clotrmazole may increase the serum concentration of halofantrine. Extreme caution, with possibly increased monitoring of cardiac status (e.g., ECG), should be used with concurrent use of halofantrine with any moderate CYP3A4 inhibitor(s).
  • Lurasidone CYP3A4 Inhibitors (Moderate) such as clotrimazole may increase the serum concentration of lurasidone. Limit adult lurasidone dose to 40 mg/day in patients receiving a moderate CYP3A4 inhibitor.
  • Ranolazine CYP3A4 Inhibitors (Moderate) such as clotrimazole may increase the serum concentration of ranolazine. Limit the ranolazine dose to a maximum of 500mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, erythromycin, etc.). Monitor for increased effects/toxicity of ranolazine during concomitant use.
  • Tacrolimus The antifungal, Clotrimazole, may increase serum concentrations of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Clotrimazole therapy is initiated, discontinued or altered.
  • Tamsulosin Clotrimazole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Clotrimazole is initiated, discontinued, or dose changed.
  • Tolterodine Clotrimazole may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
  • Tolvaptan CYP3A4 Inhibitors (Moderate) may increase the serum concentration of tolvaptan. Coadministration of a strong CYP3A4 inhibitor with tolvaptan is contraindicated.
  • Tramadol Clotrimazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
  • Trazodone The CYP3A4 inhibitor, Clotrimazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Clotrimazole is initiated, discontinued or dose changed.
Liều Lượng & Cách Dùng : Cream - Intravaginal
Cream - Topical
Dữ Kiện Thương Mại
Giá thị trường
Nhà Sản Xuất
  • Công ty : Bayer
    Sản phẩm biệt dược : Canesten
  • Công ty : Dr. August Wolff
    Sản phẩm biệt dược : Canifug
  • Công ty : Taro
    Sản phẩm biệt dược : Clotrimaderm
  • Công ty : Bayer
    Sản phẩm biệt dược : Empecid
  • Công ty :
    Sản phẩm biệt dược : FemCare
  • Công ty : Cipla
    Sản phẩm biệt dược : Fungicip
  • Công ty : Schering-Plough
    Sản phẩm biệt dược : Gyne-Lotrimin
  • Công ty : Schering-Plough
    Sản phẩm biệt dược : Lotrimin
  • Công ty : Bayer
    Sản phẩm biệt dược : Mycelex
  • Công ty :
    Sản phẩm biệt dược : Myclo-Derm
  • Công ty :
    Sản phẩm biệt dược : Myclo-Gyne
Đóng gói
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB00257
PubChem Compound
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=2812
PubChem Substance
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46507927
KEGG Compound
http://www.genome.jp/dbget-bin/www_bget?cpd:C06922
KEGG Drug
http://www.genome.jp/dbget-bin/www_bget?drug:D00282
ChemSpider
http://www.chemspider.com/Chemical-Structure.2710.html
BindingDB
http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=31774
National Drug Code Directory
http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/54868-5463-0
PharmGKB
http://www.pharmgkb.org/drug/PA449057
Wikipedia
http://en.wikipedia.org/wiki/Clotrimazole
RxList
http://www.rxlist.com/cgi/generic2/clotrimaz.htm
Drugs.com
http://www.drugs.com/mtm/clotrimazole.html
... loading
... loading